Infection streptococcique invasive sevère

Severe invasive streptococcal infection refers to disease caused by group A Streptococcus when the bacteria invade normally sterile body sites, representing a clinical form of streptococcal disease ^[1]. The causative organism is a gram-positive, chain-growing coccus showing beta-hemolysis and classified as Lancefield group A ^[1].

Invasive illness may manifest as severe cellulitis with bloodstream involvement, pneumonia, necrotizing fasciitis, or streptococcal toxic shock syndrome ^[1]. These presentations reflect tissue invasion beyond superficial or mucosal colonization ^[1].

Public health surveillance tracks invasive group A streptococcal disease, with the highest rates observed in older adults ^[1]. Documented outbreaks have occurred in healthcare and long-term-care settings, marking these as key occurrence contexts ^[1].

The bacteria most often spread person to person through respiratory droplets or contact with infected secretions such as saliva, wound discharge, or nasal fluids ^[1]. Healthcare-associated transmission has been documented, while environmental spread via surfaces or fomites is possible but likely less common ^[1].

Reducing exposure, ensuring prompt diagnosis and treatment, applying appropriate infection-control precautions, and using targeted prophylaxis in selected situations help limit spread ^[1]. No vaccine is currently available, so non-pharmaceutical measures remain the primary prevention approach ^[1].

1. 1 US Centers for Disease Control and Prevention. Clinical Considerations for Group A Streptococcus | Group A Strep | CDC [Internet]. cited 23 Oct 2026. Available from: https://www.cdc.gov/group-a-strep/hcp/clinical-guidance/index.html